Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Relacorilant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corcept Gets Complete Response Letter For Relacorilant
    Corcept Gets Complete Response Letter For Relacorilant

    31 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251231309474/en/Corcept-Receives-Complete-Response-Letter-for-Relacorilant-as-a-Treatment-for-Patients-with-Hypercortisolism

    BUSINESSWIRE
    31 Dec 2025
    Share Share
    Corcept’s Relacorilant Benefits PARPi-Treated Ovarian Cancer
    Corcept’s Relacorilant Benefits PARPi-Treated Ovarian Cancer

    19 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251019109551/en/Corcept-Presents-ESMO-2025-Late-Breaker-Relacorilant-Demonstrates-Benefit-in-Patients-with-Platinum-Resistant-Ovarian-Cancer-with-Prior-PARP-Inhibitor-Treatment

    BUSINESSWIRE
    19 Oct 2025
    Share Share
    Corcept Seeks EMA Approval For Relacorilant
    Corcept Seeks EMA Approval For Relacorilant

    14 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251014154513/en/Corcept-Submits-Marketing-Authorization-Application-to-European-Medicines-Agency-for-Relacorilant-as-a-Treatment-for-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    14 Oct 2025
    Share Share
    Corcept Shares ROSELLA Trial Data in Ovarian Cancer at ESMO
    Corcept Shares ROSELLA Trial Data in Ovarian Cancer at ESMO

    22 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250922541539/en/Corcept-to-Present-New-Late-Breaking-Data-From-Pivotal-ROSELLA-Trial-of-Relacorilant-in-Platinum-Resistant-Ovarian-Cancer-at-ESMO-2025

    BUSINESSWIRE
    22 Sep 2025
    Share Share
    FDA Files Corcept’s Relacorilant for Platinum-Resistant Ovarian
    FDA Files Corcept’s Relacorilant for Platinum-Resistant Ovarian

    10 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250910770269/en/FDA-Files-Corcepts-New-Drug-Application-for-Relacorilant-as-a-Treatment-for-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    10 Sep 2025
    Share Share
    Corcept Submits NDA for Ovarian Cancer Drug Relacorilant
    Corcept Submits NDA for Ovarian Cancer Drug Relacorilant

    14 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250714921466/en/Corcept-Submits-New-Drug-Application-for-Relacorilant-as-a-Treatment-for-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    14 Jul 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.